TheraGenetics Appoints Robert McBurney, Ph.D. As Executive Vice President

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today the appointment of Robert N. McBurney, Ph.D., to Executive Vice President. In this newly created role, Dr. McBurney will be responsible for leading the company’s global business development and partnership strategy and will report to Richard Kivel, CEO of TheraGenetics.